Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Summary

A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations

Timeline

Start

2019-09-04

Primary completion

2024-04-01

Completion

2024-04-01

Outcome

Outcome not reported

Stopped (Enrollment): “Study was closed early due to slow enrollment.”

Drugs

Indications